跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
topoisomerase I inhibitors (cancer)
首页
药物
topoisomerase I inhibitors (cancer)
topoisomerase I inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Combinations of DMXAA and other anti-cancer agents
申请人: CANCER REC TECH LTD
优先权: 2001
CN
EP
US
15 件公开
PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
申请人: CYBREXA 2 INC
优先权: 2019
CN
EP
US
WO
9 件公开
BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY
申请人: IMMUNOMEDICS INC
优先权: 2020
CN
EP
US
WO
4 件公开
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID
申请人: PHARMA MAR SA
优先权: 2010
CN
EP
US
4 件公开
CANCER TREATMENT USING TOPOISOMERASE I INHIBITORS AND PLK1 INHIBITORS
申请人: CARDIFF ONCOLOGY INC
优先权: 2022
EP
US
WO
3 件公开
PEPTIDE CONJUGATES OF CAMPTOTHECIN ANALOGS AND USES THEREOF
申请人: THERATECHNOLOGIES INC
优先权: 2023
CN
EP
WO
3 件公开
ONCOLYTIC ADENOVIRUS AND TOPOISOMERASE I INHIBITORS FOR USE IN TREATING A CANCER
申请人: THERIVA BIOLOGICS S L
优先权: 2023
CN
EP
WO
3 件公开
ALC1 INHIBITORS FOR USE IN TREATING CANCER BY POTENTIATING THE EFFECTS OF SEVERAL CLASSES OF APPROVED CANCER DRUGS
申请人: EISBACH BIO GMBH
优先权: 2023
CN
EP
WO
3 件公开
CANCER THERAPY USING A COMBINATION OF HSP90 INHIBITORS WITH TOPOISOMERASE I INHIBITORS
申请人: SYNTA PHARMACEUTICALS CORP
优先权: 2011
EP
US
3 件公开
Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
申请人: PREVOST GREGOIRE
优先权: 2003
US
3 件公开
第 1 / 3 页
上一页
下一页
药物
反馈